$19.34
0.94% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$19.34
-0.16 0.82% 1M
-8.51 30.56% 6M
-7.31 27.43% YTD
-7.41 27.70% 1Y
-14.60 43.02% 3Y
-22.54 53.82% 5Y
-2.06 9.63% 10Y
-2.06 9.63% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.18 0.94%

Key metrics

Basic
Market capitalization
$555.8m
Enterprise Value
$290.3m
Net debt
positive
Cash
$275.9m
Shares outstanding
29.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.6 | 1.9
EV/Sales
0.8 | 1.0
EV/FCF
8.4
P/B
1.2
Financial Health
Equity Ratio
85.8%
Return on Equity
4.0%
ROCE
-4.7%
ROIC
-8.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$346.3m | $299.8m
EBITDA
$16.0m | $3.7m
EBIT
$-23.1m | $-77.9m
Net Income
$-9.5m | $-70.4m
Free Cash Flow
$34.5m
Growth (TTM | estimate)
Revenue
20.4% | -9.7%
EBITDA
418.1% | -82.9%
EBIT
-46.3% | -998.3%
Net Income
-205.5% | -485.9%
Free Cash Flow
71.5%
Margin (TTM | estimate)
Gross
81.0%
EBITDA
4.6% | 1.2%
EBIT
-6.7%
Net
-2.7% | -23.5%
Free Cash Flow
10.0%
More
EPS
$-0.3
FCF per Share
$1.2
Short interest
5.6%
Employees
761
Rev per Employee
$440.0k
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Castle Biosciences Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Castle Biosciences Inc forecast:

Buy
93%
Hold
7%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
346 346
20% 20%
100%
- Direct Costs 66 66
26% 26%
19%
280 280
19% 19%
81%
- Selling and Administrative Expenses 215 215
15% 15%
62%
- Research and Development Expense 49 49
8% 8%
14%
16 16
418% 418%
5%
- Depreciation and Amortization 39 39
263% 263%
11%
EBIT (Operating Income) EBIT -23 -23
46% 46%
-7%
Net Profit -9.47 -9.47
205% 205%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
Seeking Alpha
8 days ago
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek J. Maetzold - Founder, CEO, President & Director Frank Stokes - CFO & Treasurer Conference Call Participants Catherine Walden Ramsey Schulte - Robert W.
Positive
The Motley Fool
8 days ago
Castle (CSTL) Q2 Revenue Tops Estimates
Neutral
GlobeNewsWire
8 days ago
Delivered Q2 2025 revenue of $86 million Q 2 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 33% over Q 2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CST...
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 761
Founded 2007
Website castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today